Fast-growing peptide business faces crucial week at the FDA | STAT
Skip to Main Content
My Account
A decade of reporting from the frontiers of health and medicine
Search
Log In
Try STAT+
My Account
News
Latest
Series & Investigations
Business
Biotech
Pharma
Health Tech
Health Insurance
Hospitals
Medical Devices
Washington
Policy
FDA
NIH
Science
CRISPR
Gene Therapy
Neuroscience
Public Health
Addiction
Covid-19
Abortion
Health Disparities
Infectious Disease
Mental Health
Disease
Cancer
Cardiovascular Disease
Chronic Disease
Diabetes
Alzheimer's
Obesity
Features
Health Care Costs
The Deadliest Drug
Science, Shattered
Newsletters
Opinion
Columns
Adam Feuerstein
Matthew Herper
Ed Silverman
Reports
E-books
Podcasts
Tools & Trackers
CRISPR Tracker
Breakthrough Device Tracker
Generative AI Tracker
Obesity Drug Tracker
Events
Upcoming Events
Summits
Community
STAT Wunderkinds 2026
Video
Advertise
STAT Brand Studio
What's the word?<br>Test your knowledge with our new weekday mini crossword
Start solving
STAT Plus<br>Politics
FDA staff and peptide enthusiasts set to clash at advisory panel
RFK Jr. wants to let compounding pharmacies manufacture certain peptides. Agency staff think it’s a bad idea
Manage alerts for this article
Email this article
Share this article
Adobe
By Sarah Todd and Lizzy Lawrence<br>July 23, 2026
Sarah Todd
[email protected]
Sarah covers how industries like food and tobacco affect Americans’ bodies and minds. Her interests include ultra-processed foods; smoke-free tobacco; and wellness trends like perimenopause products and peptides. Confidential tips can be sent on Signal at sarahlizchar.47.
Lizzy Lawrence
[email protected]
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health. Confidential tips can be sent on Signal at lizzylaw.53.
As more Americans experiment with synthetic peptides despite warnings about their unproven benefits and potential risks, an advisory panel to the Food and Drug Administration will meet on Thursday and Friday to discuss changes that could make peptides more accessible.
At issue is whether to allow compounding pharmacies to manufacture seven peptides that are currently designated as unsafe for them to make. The panel discussion is expected to be unusual in more ways than one.<br>Advertisement
First, many of the newly appointed members on the panel hold what critics (including FDA staff) say are conflicts of interest. The panel roster includes several physicians who prescribe peptides to patients as well as pharmacist and Tennessee state Sen. Bobby Harshbarger, whose mother, U.S. Rep. Diana Harshbarger (R-Tenn.) has advocated for looser peptide regulations. Many of these panelists were selected by the Health and Human Services Department, FDA officials previously told STAT.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
$39/month<br>Get Started<br>Totals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 months<br>Get Started<br>Then $399/year
Annual
$399
Save 15%
$399/year<br>Get Started<br>Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote<br>Request A Quote<br>Savings start at 25%!
2-10 Users
$300
Annually per user
$300/year<br>Get Started<br>$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Log In
biotechnology, FDA, Pharmaceuticals, Policy, research, RFK Jr., STAT+
Submit a correction requestReprints
Sarah Todd
Reporter, Commercial Determinants of Health
Sarah covers how industries like food and tobacco affect Americans’ bodies and minds. Her interests include ultra-processed foods; smoke-free tobacco; and wellness trends like perimenopause products and peptides. Confidential tips can be sent on Signal at sarahlizchar.47.
Lizzy Lawrence
FDA Reporter
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health. Confidential tips can be sent on Signal at lizzylaw.53.
Newsletter
The latest updates in federal health agencies, research institutes, and U.S. policy
Please enter a valid email address.<br>Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Recommended
First Opinion
First Opinion<br>July 22, 2026
What Argentina’s World Cup loss should teach American hospitals
The Readout
The Readout<br>July 22, 2026
STAT Plus: Pharma tries to tamp down broad China...